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Abstract
Objective To derive, cross validate, and externally validate a clinical
prediction model that assesses the risks of different serious bacterial
infections in children with fever at the emergency department.
Design Prospective observational diagnostic study.
Setting Three paediatric emergency care units: two in the Netherlands
and one in the United Kingdom.
Participants Children with fever, aged 1 month to 15 years, at three
paediatric emergency care units: Rotterdam (n=1750) and the Hague
(n=967), the Netherlands, and Coventry (n=487), United Kingdom. A
prediction model was constructed using multivariable polytomous logistic
regression analysis and included the predefined predictor variables age,
duration of fever, tachycardia, temperature, tachypnoea, ill appearance,
chest wall retractions, prolonged capillary refill time (>3 seconds), oxygen
saturation <94%, and C reactive protein.
Main outcomemeasures Pneumonia, other serious bacterial infections
(SBIs, including septicaemia/meningitis, urinary tract infections, and
others), and no SBIs.
Results Oxygen saturation <94% and presence of tachypnoea were
important predictors of pneumonia. A raised C reactive protein level
predicted the presence of both pneumonia and other SBIs, whereas
chest wall retractions and oxygen saturation <94% were useful to rule
out the presence of other SBIs. Discriminative ability (C statistic) to
predict pneumonia was 0.81 (95% confidence interval 0.73 to 0.88); for
other SBIs this was even better: 0.86 (0.79 to 0.92). Risk thresholds of
10% or more were useful to identify children with serious bacterial
infections; risk thresholds less than 2.5% were useful to rule out the
presence of serious bacterial infections. External validation showed good
discrimination for the prediction of pneumonia (0.81, 0.69 to 0.93);
discriminative ability for the prediction of other SBIs was lower (0.69,
0.53 to 0.86).
Conclusion A validated prediction model, including clinical signs,
symptoms, and C reactive protein level, was useful for estimating the
likelihood of pneumonia and other SBIs in children with fever, such as
septicaemia/meningitis and urinary tract infections.
Introduction
Fever is among the most common presenting signs of illness in
children. Between 10% and 20% of all paediatric visits to
hospital emergency departments are due to febrile illnesses.1-3
To differentiate children who have a benign self limiting viral
infection from the small proportion with serious bacterial
infections, many prediction models have been proposed.4-9Most
of these prediction models have not, however, been validated,9
and those that have performed poorly in emergency department
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settings.10 Typically these models also attempt to predict the
overall risk of serious bacterial infections and ignore the fact
that many different types of bacterial infection are involved,
each requiring discrete diagnostic and therapeutic management.
In one of the most robust models to date, researchers showed
that clinical signs and symptoms contribute differently to
predicting the risk of particular serious bacterial infections—that
is, pneumonia, urinary tract infection, and bacteraemia.11 In that
study they also showed that a clinical model outperformed the
clinician’s impression for assessing the risk of a serious bacterial
infection. However, this prediction model, although accurate,
involved the input of 26 clinical variables, which limits the
feasibility of using the model in many clinical settings.11 This
large number of clinical variables invites the development of a
more practical prediction model with fewer variables. In
addition, it would be worthwhile to include serum C reactive
protein level in a prediction model, an important predictor of
serious bacterial infections.12-14C reactive protein is widely used
in many emergency care settings in Europe and North America,
and point of care versions of the test have been proved to be
reliable when applied routinely in general practices.15 16 This
potentially allows the use of rapid and minimally invasive C
reactive protein tests in prediction models at the first clinical
assessment.
We developed and externally validated a clinical prediction
model, including both clinical characteristics and C reactive
protein, to identify febrile children presenting to emergency
care settings at increased risk of serious bacterial infections.
Methods
We performed a diagnostic study by first developing a clinical
prediction model, with derivation and cross validation in two
Dutch populations (Erasmus MC-Sophia and Haga-Juliana
children’s hospitals, the derivation population), then externally
validating the prediction model in a UK population (Coventry,
broad validation population).17
Derivation populations used to develop
prediction model
We prospectively enrolled all children (1 month to 15 years)
presenting with fever at the emergency department of the
ErasmusMC-Sophia children’s hospital, Rotterdam (2003-05),
and the Haga-Juliana children’s hospital, the Hague (2007), the
Netherlands. The ErasmusMC-Sophia children’s hospital is an
inner city university hospital with 9000 annual emergency
department visits (90% for basic paediatric emergency care).
The Haga-Juliana children’s hospital is an inner city teaching
hospital with 16 000 annual emergency department visits.
In Erasmus MC-Sophia febrile children were eligible to
participate in the study if fever had been noted at home in the
24 hours before presentation or body temperature measured in
the emergency department was ≥38.0°C.18 In Haga-Juliana
children were eligible if their temperature when measured
rectally in the emergency department was ≥38.0°C.19 In both
populations we excluded children with chronic comorbidity (for
example, malignancies, cystic fibrosis, severe psychomotor
retardation) and those who received antibiotics in the week
before the emergency department visit. In children who
reattended the emergency department within five days of their
first presentation we used only data from the first visit.
Laboratory tests were obtained at the discretion of the attending
emergency department doctor. Informed consent was obtained
from the parents.18
Population used for external validation
To assess broad external validation of the prediction model we
used a second large cohort of febrile children from a different
setting. This cohort consisted of children (1 month to 15 years)
who were recruited prospectively at the paediatric assessment
unit at the University Hospital Coventry andWarwickshire NHS
Trust, United Kingdom, in 2005 and 2006, if an acute infection
was suspected by the parents, the referring clinician, or the triage
nurse.20The Coventry hospital is an inner city hospital delivering
emergency care to 25 000 children annually. Children were
eligible if fever was reported by the parents or was documented
by the triaging nurse (≥38.5ºC). We excluded children with an
increased risk of recurrent serious infections, including those
with iatrogenic immunosuppression and haematological
malignancies. Laboratory tests were obtained at the discretion
of the attending emergency department doctor. Informed consent
was obtained.20
Data collection
For the Erasmus MC-Sophia and the Haga-Juliana derivation
populations trained nurses in paediatric emergency care routinely
collected data using a structured data entry application form,
which was customised for this study.21 For the Coventry
validation population a triage emergency care nurse recorded
data, including a questionnaire of presenting symptoms,
prospectively in the medical or nursing records on arrival of the
children.20 All data were collected blinded to final outcome
measures.
Outcome measures
The outcome categories were pneumonia, other serious bacterial
infections (SBIs), and no SBIs. Other SBIs included meningitis,
septicaemia, urinary tract infections, and other (erysipelas,
cellulitis, bacterial gastroenteritis, orbital cellulitis, bacterial
upper airway infection, ethmoiditis, arthritis, osteomyelitis).
The outcomes categories were chosen according to differences
in clinical presentation, diagnostic management, and frequency
of occurrence. Outcomes were defined a priori by positive
bacteriological cultures results of normal sterile sites or by
consensus diagnosis.22 In Erasmus MC-Sophia the diagnosis of
pneumonia was based on the presence of nodular infiltrations
or consolidation in the lung on chest radiographs assessed by
two board certified radiologists blinded to clinical information
(κ=0.64, 95% confidence interval 0.52 to 0.75). For the
Haga-Juliana and the Coventry populations a single radiologist,
not blinded to clinical information, interpreted the chest
radiographs. We used a one week follow-up period to rule out
the possibility of a missed diagnosis of serious bacterial infection
and to avoid verification bias.23 Follow-up consisted of telephone
contact or follow-up hospital visit and checking for repeat visits
to the emergency department or hospital admissions. All data
were collected independent of study outcome measures.
Predictor variables
We identified predictors of serious bacterial infection obtained
from keynote papers on predictive research in children with
fever, which were readily available at first assessment and have
small interobserver variability.5 7 11 20 24-39 Desaturation was
defined as oxygen saturation levels less than 94% measured by
pulse oximetry.40 In the derivation populations the nurse scored
ill appearance on a 2 point scale: ill versus non-ill appearance.
In the Coventry validation population ill appearance was defined
as a modified Yale score of more than 6.27 We included all
candidate predictor variables in the model independent of their
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statistical contribution. Continuous variables were included as
continuous to preserve maximal diagnostic information. We
tested the linearity of continuous variables with restricted cubic
splines using the Hmisc and Design library in R statistical
software (R).41 42 A linear relation with the outcomes was found
to be a good approximation for temperature and duration of
fever; for C reactive protein we used a logarithmic
transformation (lnCRP).We observed different risk profiles for
children aged less than andmore than 1 year, which wemodelled
as linear piecewise. This accounted for the differentiated risks
and the uniqueness of signs and symptoms of children in all age
groups. The risk of children aged less than 1 year was calculated:
β(age<1year)×age in years. The risk of children aged 1 or more years
was calculated with: β(age <1 year)×1+β(age ≥1 year)×(age in years−1).
Tachycardia and tachypnoea were defined according to age
specific cut-offs of advanced paediatric life support.40 43 C
reactive protein and duration of fever were truncated at the value
of three standard deviations (upper limits: C reactive protein
225 mg/L, duration of fever six days).
Statistical analysis
We constructed a polytomous multivariable prediction model
using the multinom function in the NNET library (R).42 Values
for missing data were imputed 10 times using a multiple
imputation process with the Mice logarithm (R). We assumed
missing data to be missing at random. The imputation model
included all candidate predictor variables, the outcome variable,
and several relevant variables describing case mix of the
patients, such as white blood cell count, admission to hospital,
and antibiotic prescription. (See supplementary file appendix
A for the results of the imputation process.)
Modelling procedure and validation
We developed a prediction model in the combined derivation
populations of ErasmusMC-Sophia andHaga-Juliana (n=2717).
We noted a decreasing incidence of children with septicaemia
or bacterial meningitis: 21/1750 at Erasmus MC-Sophia
(2003-05), 1/967 at Haga-Juliana (2007). Since we expect
incidence to remain low as a result of current vaccination
strategies,44 45 we introduced a 1:10 weighted analysis for
children with septicaemia or bacterial meningitis in the Erasmus
MC-Sophia population. We applied a cross validation by first
deriving the prediction model in the Erasmus MC-Sophia
population and then cross validating the prediction model in the
Haga-Juliana population and vice versa. The prediction model
was externally validated in the Coventry population. As the
variable “duration of fever” was absent in the Coventry
population, the prediction model was first refitted without this
variable in the combined derivation populations.41
Model performance
To estimate the ability to discriminate between patients with
different diagnoses we used the C statistic for pairs of patients.
A pair consisted of either a patient with pneumonia and a patient
without serious bacterial infection, or a patient with another
serious bacterial infection and a patient without a serious
bacterial infection.46 To assess calibration we compared the
predicted risks of pneumonia and other SBIs with the observed
proportions of pneumonia and other SBIs. We calculated
diagnostic performance (sensitivity, specificity, positive and
negative predictive values, and positive and negative likelihood
ratios) for several risk thresholds (from 2.5% to 30%) of children
with pneumonia compared with no SBI and other SBI and of
children with other SBI compared with no SBI and pneumonia
(epiR package in R).42 The diagnostic performance of the
validation study was calculated after adjusting for the incidence
of the outcome categories—that is, updating the model’s
constants.
Presentation of the prediction model
A digital calculator was constructed to illustrate and
accommodate potential clinical use. The calculator was based
directly on the final polytomous regression formula.
Results
In the ErasmusMC-Sophia derivation population 2784 patients
were eligible. Fifty three concerned control visits and were
excluded. A further 722 were excluded because of chronic
underlying disease and 259 owing to use of antibiotics in the
week before the emergency department visit, resulting in 1750
included children (fig 1⇓). In the Haga-Juliana derivation
population 1182 patients were eligible. Thirty two concerned
control visits and were excluded. A further 36 were excluded
because of chronic comorbidity and 147 owing to use of
antibiotics in the week before the emergency department visit,
resulting in 967 included children (fig 1). The Coventry
validation population consisted of 487 children with fever. Table
1⇓ shows the general characteristics of the two derivation
populations and the validation population.We observed a similar
prevalence of pneumonia and other SBIs for the derivation
populations but a substantially higher prevalence in the
validation population. Populations differed for some
characteristics, such as age, temperature, respiratory rate, heart
rate, oxygen saturation, and ill appearance. Table 2⇓ shows the
distribution of the predictor variables for the three outcome
categories and univariate polytomous regression coefficients in
the combined derivation population.
Model development and performance
Table 3⇓ presents the multivariable odds ratios of the prediction
model in the derivation populations. Important predictors of
pneumonia were oxygen saturation less than 94% (odds ratio
4.92, 95% confidence interval 2.53 to 9.54), body temperature
per °C (1.33, 1.05 to 1.69 per °C), tachypnoea (1.55, 0.99 to
2.42), duration of fever per day (1.24, 1.11 to 1.38 per day), and
log transformation of C reactive protein (1.89, 1.58 to 2.27).
The log transformation of C reactive protein (3.11, 2.50 to 3.87)
was also an important predictor of other SBIs. Chest wall
retractions and oxygen saturation less than 94% were useful to
rule out the presence of other SBIs. The C statistic for the
presence of pneumonia was 0.81 (95% confidence interval 0.73
to 0.88) and for other SBIs was 0.86 (0.79 to 0.92). Figure 2⇓
shows that the predicted risks for pneumonia were higher in
children who had pneumonia than in children with a diagnosis
of no SBI. The predicted risks for pneumonia in children with
other SBIs were also lower. The predicted risks for other SBIs
ranged widely in children with a diagnosis of other SBI and
were substantially higher than the predicted risks in children
with a diagnosis of pneumonia and no SBI.
In the cross validation study the C statistic for pneumonia in
the Haga-Juliana derivation population was 0.80 (95%
confidence interval 0.70 to 0.90) and for other SBIs was 0.88
(0.76 to 0.99); the corresponding values in the Erasmus
MC-Sophia derivation population were 0.77 (0.69 to 0.85) and
0.82 (0.76 to 0.88). Calibration for the cross validation study
was adequate for both outcomes (see supplementary file
appendix B).
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A model including C reactive protein performed significantly
better than a model including only clinical signs and symptoms.
The C statistic of the clinical model for the prediction of
pneumonia was 0.76 (0.68 to 0.84) and for other SBIs was 0.73
(0.66 to 0.80). Other model performance indicators also
improved substantially by adding C reactive protein (see
supplementary file appendix C). The complete case analysis
(n=373, pneumonia n=58, and other SBIs n=44, see
supplementary file appendix D) showed similar results, with a
C statistic for pneumonia of 0.80 (0.67 to 0.93) and for other
SBIs of 0.89 (0.79 to 1.00). Supplementary file appendix C
shows the additional value of C reactive protein in the complete
case analysis.
Low risk thresholds were useful to rule out the presence of
pneumonia: a risk cut-off of 2.5% had a sensitivity of 0.90 (95%
confidence interval 0.85 to 0.96) and a negative likelihood ratio
of 0.24 (0.14 to 0.40, table 4⇓ and fig 3⇓). Risk thresholds of
10% or more were useful to identify children with pneumonia:
for example, a risk threshold of 15% had a specificity of 0.92
(0.90 to 0.93) and positive likelihood ratio of 5.58 (4.31 to 7.23).
Low risk thresholds could also rule out the presence of other
SBIs: a risk threshold of 2.5% gave a sensitivity of 0.90 (0.84
to 0.96) and a negative likelihood ratio of 0.18 (0.11 to 0.30).
Higher risk thresholds were useful to identify children with
other SBIs: for example, a risk threshold of 15% had a
specificity of 0.91 (0.90 to 0.93) and a positive likelihood ratio
of 6.35 (5.16 to 7.82, table 4 and fig 3). Figure 4⇓ shows the
receiver operating characteristic curves for the prediction of
pneumonia and other SBIs. The sensitivity and specificity for
several risk thresholds are plotted in these receiver operating
characteristic curves.
External validation of prediction model
As duration of fever was not recorded in the Coventry validation
population, a model was refitted in the derivation populations
without the variable “duration of fever”: the C statistic of this
model for pneumonia was 0.80 (95% confidence interval 0.72
to 0.89) and for other SBIs was 0.86 (0.79 to 0.92), and all
predictors had similar effects (data not shown). In the Coventry
population the C statistic of this model to predict the presence
of pneumonia was 0.81 (0.69 to 0.93). The discriminative ability
of the prediction of other SBIs was substantially lower (0.69,
0.53 to 0.86). Overall, calibration was satisfactory (fig 5⇓). The
mean predicted risk of pneumonia in the Coventry population
was 11% (95% confidence interval 10% to 13%) compared with
an observed proportion of 12% (11% to 13%). The mean
predicted risk of other SBIs was 16% (15% to 18%) compared
with an observed proportion of 13% (12% to 15%). Agreement
between the predicted and observed risks was reasonable given
the low number of patients with pneumonia (n=59) or other
SBIs (n=65). For the prediction of pneumonia, the confidence
intervals of the observed probabilities covered the line of ideal
calibration (fig 5). For other SBIs the confidence intervals of
the observed probabilities covered the line of ideal calibration
in the higher risk categories (fig 5). Low risk thresholds ruled
out the presence of pneumonia. For example, a risk threshold
of 2.5% or more had a negative likelihood ratio of 0.12 (0.02
to 0.84) and sensitivity of 0.99 (0.91 to 1.00, table 5⇓). High
thresholds were useful for ruling in pneumonia. For example,
for a risk threshold of 15%, the positive likelihood ratio was
3.57 (2.58 to 4.94) and the specificity was 0.82 (0.78 to 0.87).
Diagnostic performance measures for the risk of other SBIs
were insufficient for either ruling in or ruling out the presence
of other SBIs.
Discussion
We developed and externally validated a clinical prediction
model to predict the presence of pneumonia and other serious
bacterial infections (SBIs) in children with fever presenting to
emergency care settings. Duration of fever, body temperature,
tachypnoea, and low oxygen saturation were strong predictors
of pneumonia. Chest wall retractions and low oxygen saturation
were important to rule out the presence of other SBIs. Increased
levels of C reactive protein were associated with the presence
of both pneumonia and other SBIs. Low risk thresholds less
than 2.5%were able to rule out, and high risk thresholds of 10%
or more were able to rule in, the presence of pneumonia and
other SBIs. The model was useful for ruling in and ruling out
the presence of pneumonia in external validation; discriminative
ability for other SBIs was lower.
Comparison with existing literature
Clinical prediction models in children fulfilling existing
performance standards (that is, derivation, validation, broad
validation, and implementation) are scarce.9 47 In addition, a
systematic review concluded that none of the existing clinical
prediction models for serious bacterial infections consisting of
clinical signs and symptoms had added value in intermediate
or high incidence settings, such as hospital emergency
departments.10 Therefore in our study design we developed and
validated a clinical prediction model considering many of the
required quality items for clinical prediction rules.9 Also, most
previous studies aggregate different types of serious bacterial
infections into a single outcome category,38 and only the model
by one group of researchers11 accounted for the heterogeneity
of possible outcome categories. Our approach acknowledged
that different types of serious bacterial infections involve
different clinical management and diverse clinical risk
assessment. We thus aimed to aid clinicians in distinguishing
three categories of infections in febrile children: pneumonia,
other SBIs, and no SBI (see supplementary file, a version of the
calculator is also available at www.erasmusmc.nl/feverkidstool).
In addition, the diagnostic values of clinical signs and symptoms
have often been shown in children at risk of specific outcome
measures.38 However, the challenge lies not only in identifying
children with, for example, pneumonia among children with
signs of a lower respiratory tract infection but rather in
designating risk thresholds to all children with fever. Indeed, it
has been shown that the incidence of radiographically proved
pneumonia among children with fever without a clear focus is
significant (5-9%),48-51 and was especially high in children with
raised laboratory markers (13-18%).48 51 Besides, not only did
our prediction model verify known predictors of pneumonia in
children at increased risk of a lower respiratory tract infection,
supporting the validity of our results,4 38 52 but perhaps more
importantly it also simultaneously showed that the presence of
these signs and symptoms was valuable for ruling out other
SBIs. Next, while diagnostic tests are often deployed for the
evaluation of febrile children, few studies have quantified the
value of diagnostic tests in addition to clinical signs and
symptoms.12 Previously reported clinical prediction rules on
febrile children that combined both clinical features and
laboratory markers either had poor external validity,5 18 targeted
young infants,53 or included laboratory markers regardless of
clinical signs and symptoms.54-56 C reactive protein is an
important predictor of serious bacterial infections,12-14 and we
determined its added value to clinical signs and symptoms. Our
results confirmed that C reactive protein is a strong predictor
of serious bacterial infections, and in most children C reactive
protein considerably improved risk estimates compared with
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estimates based on clinical signs and symptoms only. We did
not consider white blood cell count, as it has no added value
when C reactive protein is available,12 38 54 55 57-59 nor
procalcitonin, as it was not available at the emergency
departments and no quantitative point of care test has yet been
developed.12 14 60 61 Further research is required on these and
other markers of serious bacterial infections.
Strengths and limitations of the study
The main strength of our study is that we performed a
prospective, multicentre study involving large and diverse
cohorts of children. Secondly, we derived and cross validated
a prediction model using two large prospective cohorts and we
assessed broad validation in an external population from a
different country.41 These cohorts lacked uniformity of inclusion
criteria, data collection, and outcome measures, which is
commonly seen as a drawback when translating diagnostic
research to clinical practice. However, this lack of uniformity
reflects the diversity of clinical practice and thus forms a strong
test of external validity.47 Thirdly, we included potential
predictors in the model independent of their statistical
contribution, limiting the risk of chance findings62 63 and
increasing face validity and thereby ensuring clinical sensibility
and compliance.39 We therefore chose to include heart rate in
our model despite its limited effect. Fourthly, we incorporated
the prediction model into an actual risk assessment tool for
clinical practice.11
Our study has some limitations. Firstly, reference tests were
ordered at the doctor’s discretion. We used a follow-up period
and clinical consensus to ensure that diagnoses of serious
bacterial infections were not missed.23Webelieve this minimised
the risk of verification bias. It is an approach commonly used
in this area of research, as it would be unethical to perform
invasive tests in children if not clinically indicated. Secondly,
although our study uses routine clinical data collected by trained
emergency department nurses, interobserver variability might
influence the validity of the model.64 Thirdly, we specified three
outcome categories—that is, pneumonia, other SBIs, and no
SBI, and were not able to derive a prediction model for
septicaemia or meningitis as separate outcome categories. Given
further reductions in incidence of invasive bacterial infections
in most high income countries,45 this is unlikely to be possible
in future research. Also, a limited number of cases of other SBIs
in the external validation population and the large diversity of
diagnoses in this group restricted the model’s generalisability
to other SBIs.63 Fourthly, C reactive protein was measured at
the discretion of the doctor and, not surprisingly, was obtained
more consistently in children at a higher risk of serious bacterial
infection (see supplementary file appendix E). Excluding
children without C reactive protein would have selected a
subpopulation of children at high risk of serious bacterial
infections, as shown in the complete case analysis, and thus
limited the generalisability of our prediction model. Missing
values of C reactive protein were imputed to be able to analyse
observed values from the other predictors, which resulted in
higher precision of predictor effects.65 66
Implications for clinical practice
The roles of alarming signs or pathognomic disease specific
features of serious bacterial infections, such as petechiae, are
limited in practice, as the prevalence of these features is
low.38 67 68 Although these signs are highly specific, they have
poor sensitivity and will apply only to a small number of
children. We suggest that a more useful diagnostic strategy
should involve prediction models that combine signs and
symptoms and are particularly focused on providing better
clinical discrimination for children in the so called “grey
area”—that is, where diagnostic uncertainty is greatest. The
proposed application of the model (a digital calculator, as shown
in the supplementary file, also available at www.erasmusmc.nl/
feverkidstool) reflects how we believe different risk levels of
serious bacterial infection should be managed. Foremost, a
prediction model should discriminate between children at high
and low risk of serious bacterial infections (that is, pneumonia,
other SBIs, including urinary tract infection and
sepsis/meningitis compared with those without serious bacterial
infections). This is helpful to identify children who may need
further tests, such as additional blood tests or chest radiography,
and guide the need for antibiotic prescribing. Also, prediction
models should be combined with clear safety net instructions
on when to access the health system if the clinical presentation
changes, since no clinical prediction rule can achieve perfect
sensitivity, especially as children present at different stages in
the evolution of their illness.67 69 Considering the typical course
of pneumonia and most other common serious bacterial
infections and the diagnostic performance of low risk thresholds,
we believe that a watchful waiting approach is acceptable in
children at low risk. Furthermore, the harms of not routinely
testing for C reactive protein should be weighed against the
harms and costs of testing for C reactive protein in all febrile
children. Even in children at a clinical low suspicion of serious
bacterial infections, not carrying out tests for C reactive protein
would still lead to missed cases of serious bacterial infections,
albeit in only a small number of children. Moreover, although
C reactive greatly improves risk predictions, this will not
necessarily lead to better diagnostic or therapeutic management
of febrile children if specific risk thresholds are not reached.70
At present no established risk thresholds for ordering additional
diagnostic tests or initiating antibiotic therapy exist, posing an
unanswered dilemma. In addition, the pretest probability of
having a serious bacterial infection is determined by the
incidence. Adjusting the prediction model for this pretest
probability before implementation elsewhere enhances the risk
predictions. Hence, risk thresholds should be chosen accordingly
for each particular setting and each potential outcome category.
Implications for future research
We tried to create a framework and set a standard for future
research in the topic of diagnostic research in febrile children.
As many other potential diagnostic tests are being
reported,12 14 61 71 their diagnostic value should always be
evaluated in combination with clinical signs and symptoms and
diagnostic tests that already have proved their additional value,
and take into account more than one potential outcome category.
We strongly suggest validating and updating prediction models,
derived from prospective data, rather than developing new ones.
A further validation study of our prediction model, in particular
to improve on the discriminative ability of other SBI, is
recommended. Finally, studies that focus on the impact of
prediction models on clinical practice, ideally by trials of a
clinical decision support system, are an essential final step when
implementing prediction models in clinical practice.9 72 73
Therefore, the use and impact of this prediction model, as well
as the calculator as a diagnostic tool, on clinical practice should
be investigated in future studies.
Conclusion
Clinical signs, symptoms, and C reactive protein are useful for
estimating the likelihood of pneumonia and other SBIs in
children with fever through the presented prediction model. If
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further validated, this model may well support doctors in their
diagnostic work-up and therapeutic decision making.
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Tables
Table 1| General characteristics of included populations. Values are numbers (percentages) unless stated otherwise
External validation populationDerivation population
Characteristics Coventry (n=487)Haga-Juliana (n=967)Erasmus MC-Sophia (n=1750)
Predictor variables
2.5 (1.3-6.3)1.5 (0.7-3.2)1.8 (0.9-3.7)Median (interquartile range) age (years)
n=487n=964n=1750Sex
215 (44)531 (55)998 (57)No (%) male
NA807n=1185
2.0 (1.0-3.0)2.0 (1.0-3.0)Median (interquartile range) duration of
fever (days)
n=483n=967n=1699
38.1 (37.4-39.0)38.8 (38.3-39.4)39.0 (38.3-39.7)Median (interquartile range) temperature
(ºC)
n=415n=183n=819
34 (24-40)48 (40-60)36 (28-48)Median (interquartile range) respiratory rate
(breaths/min)
n=480n=473n=914
146 (122-163)156 (140-172)140 (120-160)Median (interquartile range) heart rate
(beats/min)
46 (9)43 (4)41 (2)Oxygen saturation <94%
8 (2)9 (1)96 (5)Capillary refill time >3 seconds
91 (19)108 (11)97 (6)Chest wall retractions
171 (73)65 (7)520 (30)Ill appearance
n=209n=317n=780
48 (18 to 123)22 (7 to 56)21 (7 to 54)Median (interquartile range) C-reactive
protein (mg/L)
Outcome measures
124 (25)119 (12)222 (13)Serious bacterial infection:
59 (12)66 (7)105 (6)Pneumonia
28 (6)38 (4)50 (3)Urinary tract infection
3 (1)1 (0)21 (1)Septicaemia/meningitis
34 (7)14 (1)46 (3)Other*
363 (75)848 (88)1528 (87)None
When data were not available for all patients, total number of available data noted.
*Includes erysipelas, cellulitis, bacterial gastroenteritis, cellulitis orbitae, bacterial upper airway infection, ethmoiditis, arthritis, and osteomyelitis.
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Table 2| Predictor distribution and univariate polytomous odds ratios of derivation population (Erasmus MC-Sophia and Haga-Juliana
combined). Values are numbers (percentages) unless stated otherwise
Odds ratio (95% CI)†
Other SBIs* (n=170)Pneumonia (n=171)No SBI (n=2376)Variables Other SBIsPneumonia
Age:
——4.13 (3.52 to 4.75)3.12 (2.71 to 3.53)2.60 (2.49 to 2.71)Mean (95% CI) age
0.42‡ (0.21 to 0.83)5.89‡ (2.26 to 15.37)———1 month to <1 year
1.18‡ (1.12 to 1.24)1.01‡ (0.96 to 1.07)——≥1 year
2.09 (1.50 to 2.93)1.19 (0.87 to 1.63)98 (58)80 (47)1008 (42)Female
1.25 (1.12 to 1.38)1.43 (1.31 to 1.57)2.5 (2.2 to 2.8)¶3.0 (2.7 to 3.3)¶2.0 (1.9 to 2.1)¶Duration of fever (days)§
1.22(1.00 to 1.50)1.71 (1.41 to 2.07)39.1 (39.0 to 39.2)¶39.3 (39.2 to 39.4)¶38.9 (38.9 to 39.0)¶Temperature (°C)
0.98 (0.52 to 1.82)2.10 (1.36 to 3.23)98 (58)127 (74)1377 (58)Tachypnoea
1.03 (0.69 to 1.53)1.36 (0.95 to 1.94)73 (43)86 (50)1015 (43)Tachycardia
0.03 (0.00 to 12.44)5.90 (3.55 to 9.80)0 (0 )23 (13)61 (3)Oxygen saturation <94%
1.25 (0.56 to 2.80)1.15 (0.52 to 2.53)13 (8)7 (4)85 (4)Capillary refill time >3 sec
0.02 (0.00 to 1.31)2.11 (1.35 to 3.32)2 (1)25 (15)178 (8)Chest wall retractions
1.62 (1.12 to 2.33)1.80 (1.28 to 2.52)57 (34)53 (31)475 (20)Ill appearance
3.02 (2.49 to 3.65)2.26 (1.90 to 2.69)4.16 (3.96 to 4.36)¶3.86 (3.62 to 4.10)¶2.52 (2.43 to 2.60)¶lnCRP (ln(mg/L))**
SBI=serious bacterial infection.
*Other SBIs include septicaemia/meningitis, urinary tract infections, and others.
†No SBI as reference group.
‡Odds ratio: children <1 year=exp(β(age <1 year)×age in years), children ≥1 year=exp(1×β(age <1 year)+(age in years−1)×β(age ≥1 year)).
§Maximum duration six days.
¶Mean (95% CI).
**Maximum value ln(225) mg/L.
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Table 3| Polytomous odds ratios of final prediction model
Odds ratio (95% CI)
Variables Other SBIsPneumonia
Age:
0.18* (0.08 to 0.39)2.76* (0.99 to 7.69)1 month to <1 year
1.11* (1.05 to 1.18)1.01* (0.95 to 1.08)≥1 year
2.01 (1.37 to 2.94)1.14 (0.81 to 1.61)Female
0.97 (0.86 to 1.10)1.24 (1.11 to 1.38)Duration of fever (days)†
0.98 (0.75 to 1.26)1.33 (1.05 to 1.69)Temperature (°C)
0.90 (0.48 to 1.69)1.55 (0.99 to 2.42)Tachypnoea
0.98 (0.62 to 1.56)0.96 (0.63 to 1.46)Tachycardia
0.04 (0.00 to 19.22)4.92 (2.53 to 9.54)Oxygen saturation <94%
1.35 (0.53 to 3.42)0.84 (0.33 to 2.10)Capillary refill time >3 sec
0.02 (0.00 to 1.85)1.61 (0.93 to 2.76)Chest wall retractions
1.31 (0.84 to 2.05)1.18 (0.79 to 1.75)Ill appearance
3.11 (2.50 to 3.87)1.89 (1.58 to 2.27)lnCRP (ln(mg/L))‡
0.86 (0.79 to 0.92)0.81 (0.73 to 0.88)C statistic
SBIs=serious bacterial infections; lnCRP=log transformation of C reactive protein.
*Odds ratio: children <1 year=exp(β(age <1 year)×age in years), children ≥1 year=exp(1×β(age <1 year)+(age in years−1)×β(age ≥1 year)).
†Maximum six days.
‡Maximum ln(225) mg/L.
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Table 4| Diagnostic performance measures at different risk thresholds of final prediction model (derivation population)
Likelihood ratio (95% CI)Predictive value (95% CI)
Specificity (95% CI)Sensitivity (95% CI)
Outcomes and risk
thresholds NegativePositiveNegativePositive
Pneumonia:
0.24 (0.14 to 0.40)1.51 (1.38 to 1.65)0.98 (0.97 to 0.99)0.09 (0.08 to 0.11)0.40 (0.36 to 0.45)0.90 (0.85 to 0.96)≥2.5%
0.33 (0.24 to 0.46)2.18 (1.96 to 2.44)0.98 (0.97 to 0.99)0.13 (0.11 to 0.15)0.64 (0.61 to 0.67)0.78 (0.71 to 0.86)≥5%
0.47 (0.37 to 0.60)3.73 (3.08 to 4.51)0.97 (0.96 to 0.98)0.20 (0.16 to 0.24)0.84 (0.82 to 0.85)0.60 (0.50 to 0.71)≥10%
0.58 (0.48 to 0.70)5.58 (4.31 to 7.23)0.96 (0.95 to 0.97)0.27 (0.21 to 0.33)0.92 (0.90 to 0.93)0.47 (0.37 to 0.56)≥15%
0.85 (0.79 to 0.92)11.07 (6.57 to 18.66)0.95 (0.94 to 0.96)0.43 (0.29 to 0.56)0.99 (0.98 to 0.99)0.16 (0.10 to 0.22)≥30%
Other SBIs:
0.18 (0.11 to 0.30)2.06 (1.87 to 2.26)0.99 (0.98 to 1.00)0.12 (0.10 to 0.14)0.56 (0.53 to 0.60)0.90 (0.84 to 0.96)≥2.5%
0.26 (0.18 to 0.36)2.92 (2.60 to 3.27)0.98 (0.98 to 0.99)0.16 (0.14 to 0.19)0.72 (0.70 to 0.74)0.82 (0.74 to 0.89)≥5%
0.35 (0.26 to 0.46)4.84 (4.10 to 5.71)0.98 (0.97 to 0.99)0.25 (0.20 to 0.29)0.85 (0.84 to 0.87)0.70 (0.61 to 0.79)≥10%
0.49 (0.40 to 0.60)6.35 (5.16 to 7.82)0.97 (0.96 to 0.98)0.30 (0.25 to 0.35)0.91 (0.90 to 0.93)0.55 (0.46 to 0.64)≥15%
0.83 (0.76 to 0.91)9.12 (5.54 to 15.01)0.95 (0.94 to 0.96)0.38 (0.26 to 0.50)0.98 (0.97 to 0.99)0.19 (0.12 to 0.26)≥30%
SBIs=serious bacterial infections.
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Table 5| Diagnostic performance measures at different risk thresholds of final prediction model (validation population)
Likelihood ratio (95% CI)Predictive value (95% CI)
Specificity (95% CI)Sensitivity (95% CI)
Outcomes and risk
thresholds NegativePositiveNegativePositive
Pneumonia:
0.12 (0.02 to 0.84)1.16 (1.10 to 1.22)0.99 (0.91 to 1.00)0.14 (0.11 to 0.17)0.14 (0.10 to 0.18)0.99 (0.91 to 1.00)≥2.5%
0.23 (0.09 to 0.56)1.48 (1.31 to 1.66)0.97 (0.93 to 1.00)0.17 (0.13 to 0.21)0.38 (0.33 to 0.44)0.91 (0.81 to 1.00)≥5%
0.36 (0.21 to 0.59)2.39 (1.92 to 2.99)0.95 (0.92 to 0.98)0.25 (0.18 to 0.31)0.69 (0.63 to 0.74)0.75 (0.61 to 0.90)≥10%
0.45 (0.30 to 0.67)3.57 (2.58 to 4.94)0.94 (0.91 to 0.97)0.33 (0.24 to 0.42)0.82 (0.78 to 0.87)0.63 (0.47 to 0.78)≥15%
0.69 (0.56 to 0.85)6.81 (3.70 to 12.55)0.91 (0.88 to 0.94)0.48 (0.31 to 0.66)0.95 (0.92 to 0.98)0.34 (0.21 to 0.48)≥30%
Other SBIs:
0.59 (0.34 to 1.02)1.21 (1.04 to 1.40)0.92 (0.86 to 0.97)0.16 (0.12 to 0.19)0.33 (0.28 to 0.39)0.80 (0.68 to 0.93)≥2.5%
0.56 (0.36 to 0.89)1.36 (1.14 to 1.64)0.92 (0.87 to 0.97)0.17 (0.13 to 0.22)0.45 (0.40 to 0.51)0.74 (0.61 to 0.87)≥5%
0.49 (0.33 to 0.72)1.87 (1.49 to 2.34)0.93 (0.89 to 0.97)0.22 (0.17 to 0.28)0.63 (0.57 to 0.68)0.70 (0.57 to 0.83)≥10%
0.52 (0.36 to 0.75)2.23 (1.69 to 2.92)0.93 (0.89 to 0.96)0.26 (0.19 to 0.33)0.72 (0.67 to 0.77)0.62 (0.48 to 0.77)≥15%
0.65 (0.51 to 0.82)4.00 (2.50 to 6.39)0.91 (0.88 to 0.94)0.38 (0.26 to 0.51)0.90 (0.86 to 0.93)0.42 (0.28 to 0.55)≥30%
SBIs=serious bacterial infections.
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Figures
Fig 1 Flowchart of derivation populations
Fig 2 Predicted risks of pneumonia and other serious bacterial infections (SBIs) in children with a diagnosis of pneumonia,
other SBIs, or no SBI
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Fig 3 Positive and negative likelihood ratios plotted for several risk thresholds for predicted risks of pneumonia and other
serious bacterial infections (SBIs)
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Fig 4 Receiver operating characteristic curve for risk of pneumonia and other serious bacterial infections (SBIs). Sensitivity
and specificity of several risk thresholds of the prediction model are plotted
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Fig 5 Calibration plot of predicted risks of pneumonia and other serious bacterial infections (SBIs) and observed frequencies
(95% confidence interval). Triangles represent mean (predicted versus observed) risk estimates of outcomes by fifths of
predicted risk. Dashed diagonal line represents ideal calibration. Distribution of predicted risks of patients with outcome
(pneumonia n=59, other SBIs n=65) and other patients (pneumonia n=428, other SBIs n=422) is shown at bottom of graph
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